Retrovirus‐Mediated Gene Transfer into Hematopoietic Stem Cells
Annals of the New York Academy of Sciences, ISSN: 1749-6632, Vol: 507, Issue: 1, Page: 242-251
1987
- 9Citations
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef8
- Captures2
- Readers2
Book Chapter Description
The ability to transfer new genetic information into murine and human hematopoietic cells with retrovirus vectors offers a powerful approach to identifying the molecular mechanisms governing stem cell development. The newly integrated provirus also serves as a clonal marker for elucidating the lineage relationships of the cells in the stem cell hierarchy. High efficiency gene transfer into human cells opens the way to developing new therapy for treating genetic diseases by introducing functional genes into deficient cells. Present transplantation technology would only permit gene therapy with bone marrow cells. However, as gene transfer and transplantation technologies improve it may be possible to consider treating diseases that affect other organs and tissues. I would like to acknowledge the support of Alan Bernstein and R. Phillips in whose labs the murine work was carried out during a post-doctoral fellowship. I also thank Sharon Kerbel for excellent assistance in the preparation of this manuscript.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0023613957&origin=inward; http://dx.doi.org/10.1111/j.1749-6632.1987.tb45805.x; http://www.ncbi.nlm.nih.gov/pubmed/3327416; https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.1987.tb45805.x; https://dx.doi.org/10.1111/j.1749-6632.1987.tb45805.x
Wiley
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know